Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Melius Pharma logo — Clinical stage biopharma company developing treatments for d...

Melius Pharma

Clinical stage biopharma company developing treatments for diseases with high unmet needs at a reduced development risk

Founded 2021 Sweden Sweden 3 employees Series A Total: $18.00M Health Care, Pharmaceutical

General Information

Company Name Melius Pharma
Founded Year 2021
Location Sweden Sweden +1
Employees 3
Industries Health Care, Pharmaceutical
Funding Stage Series A
Social

Get notified when Melius Pharma moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Melius Pharma

Melius Pharma: A Swedish clinical stage pharmaceutical company, is focused on developing treatments for severe diseases with high unmet clinical needs at a reduced development risk. The company's flagship product, ME-015 (suplatast tosilate), is a first-in-class, safe, and well-tolerated oral treatment for chronic cough in idiopathic pulmonary fibrosis (IPF) patients. ME-015, a new chemical entity in all geographies outside of Japan, has shown promising results in exploratory cough data in several indications. Melius Pharma's recent venture round investment of kr18.00M at 03 May 2022 was led by Fåhraeus Startup and Growth. The company's innovative approach to addressing diseases with high unmet needs in the Health Care and Pharmaceutical industries makes it an attractive prospect for venture capital firms seeking opportunities in the biopharma sector. For more details, interested parties can access the clinical trial information for Melius Pharma's first clinical trial, COSMIC-IPF, on clinicaltrial.gov (study NCT05983471). Additionally, a 2-minute video explaining cough related to Idiopathic Pulmonary Fibrosis and ME-015's mechanism of action is available on Vimeo (https://vimeo.com/811293278). With its unique approach and promising developments, Melius Pharma presents a compelling investment opportunity in the pharmaceutical landscape.

Taxonomy: clinical stage biopharma, drug development, treatment development, chronic cough, pulmonary fibrosis, clinical trial, exploratory data, new chemical entity, interstitial lung diseases, pharmaceutical company, ME-015, suplatast tosilate, oral treatment, high unmet clinical needs

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A •••••• 1 •••• •••• 03 May 2022

Melius Pharma Alternatives & Competitors

Melius Pharma vs
NeRRe Therapeutics Ltd
NeRRe Therapeutics Ltd United Kingdom

Developing a breakthrough treatment for the disabling chronic cough associated with idiopathic pulmo...

Series B
9 employees
Biotechnology, Health Care
Melius Pharma vs
Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. United States

Clinical-stage biopharmaceutical company

Post Ipo Equity
34 employees
Biotechnology, Health Care
Compare Melius Pharma vs Trevi Therapeutics, Inc.
Melius Pharma vs
Vicore Pharma AB
Vicore Pharma AB Sweden

Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class...

Post Ipo Equity
41 employees
Biopharma, Biotechnology
Compare Melius Pharma vs Vicore Pharma AB
Also compare with: Melius Pharma vs Activaero GmbH Activaero GmbH

FAQ About Melius Pharma

Clinical stage biopharma company developing treatments for diseases with high unmet needs at a reduced development risk
Melius Pharma was founded in 2021.
Melius Pharma is headquartered in Sweden.
Melius Pharma operates in the following industries: Health Care, Pharmaceutical.
Melius Pharma has approximately 3 employees.
Melius Pharma has completed 1 funding round, raising a total of $18.00M. The latest funding stage is Series A.
Top alternatives and competitors to Melius Pharma include NeRRe Therapeutics Ltd, Trevi Therapeutics, Inc., Vicore Pharma AB, Endeavor BioMedicines, Inversago Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Melius Pharma and NeRRe Therapeutics Ltd are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Melius Pharma and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy